Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,465 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Control Clear all
Not yet recruiting Not applicable Interventional

OCM™ Treatment With Routine Care in Venous Leg Ulcers Compared to Routine Care Treatment Alone.

NCT07754526
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
Omeza OCM™ Wound Matrix, Routine Care
Device · Procedure
Lead sponsor
Omeza, LLC
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

NCT03995108
View directory record Official record
Conditions
WHIM Syndrome
Interventions
Mavorixafor, Placebo
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
6
States / cities
San Diego, California • Thousand Oaks, California • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Digital Patient Decision Aid to Increase Sexually Transmitted Infection Testing in the Emergency Department: The STIckER Study

NCT06014177
View directory record Official record
Conditions
STI, Sexually Transmitted Infection (STI), Sexually Transmitted Disease (STD)
Interventions
STIckER, Control
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
14 Years to 24 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults

NCT00239577
View directory record Official record
Conditions
Dengue
Interventions
Live attenuated tetravalent dengue vaccine, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Magnesium Supplementation in People With XMEN Syndrome

NCT02496676
View directory record Official record
Conditions
XMEN
Interventions
Magnesium L-threonate, Placebo, Intravenous (IV) magnesium sulfate (MgSO4)
Dietary Supplement · Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Not applicable Interventional Results available

Antibiotic Selection Using Next Generation Sequencing vs Urine Culture

NCT04404855
View directory record Official record
Conditions
Kidney Stone, Renal Stone, Infection, Bacterial
Interventions
NGS + Antibiotic Recommendation, Standard of Care treatment
Other · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 23, 2026, 6:09 AM EDT
Terminated Phase 4 Interventional

Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection

NCT00407147
View directory record Official record
Conditions
Infection, Bacterial Infection, Sepsis
Interventions
Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor
Device
Lead sponsor
Brahms AG
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
St Louis, Missouri • Camden, New Jersey • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Oct 23, 2026, 6:09 AM EDT
Completed No phase listed Observational

The Significance of Funguria in Hospitalized Patients

NCT00787085
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Not listed
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
Not listed
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
2
States / cities
Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2008 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 2 Interventional Results available

Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD

NCT01695291
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Minocycline, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
8 Years to 20 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 23, 2026, 6:09 AM EDT
Completed No phase listed Observational

Developing and Maintaining a Central Venous Catheter Registry

NCT01165411
View directory record Official record
Conditions
Infection
Interventions
Not listed
Lead sponsor
Lehigh Valley Hospital
Other
Eligibility
Not listed
Enrollment
4,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

NCT02652780
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study

NCT00002146
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections, Hypocalcemia
Interventions
Magnesium sulfate, Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study)

NCT01161446
View directory record Official record
Conditions
HIV
Interventions
Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test, Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test
Behavioral · Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)

NCT03577171
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H0731, SOC ETV, Placebo Oral Tablet
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Coronado, California • Los Angeles, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

NCT03176134
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Tedizolid phosphate, Comparator
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Not applicable Interventional Results available

CONTINUED ACCESS PROTOCOL: Demonstration of the Safety and Effectiveness of ReCell® Combined With Meshed Skin Graft for Reduction of Donor Area in the Treatment of Acute Burn Injuries

NCT02994654
View directory record Official record
Conditions
Burns
Interventions
ReCell
Device
Lead sponsor
Avita Medical
Industry
Eligibility
5 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community Level Primary Prevention of Dating and Sexual Violence in Middle Schools

NCT03473067
View directory record Official record
Conditions
Violence
Interventions
Social Norms Marketing Campaign, Capacity Building
Behavioral · Other
Lead sponsor
Lifespan
Other
Eligibility
10 Years and older
Enrollment
4,344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Love Infection: A Dramatized Story Intervention (Telenovela/Soap Opera) for HIV Prevention

NCT05358366
View directory record Official record
Conditions
HIV Infections
Interventions
Infeccion de Amor (Love Infection)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine
Drug · Biological
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 54 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

NCT05897541
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
S-217622, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
Not listed
Enrollment
3,701 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
95
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 6:09 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

NCT06431373
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Interventions
Brepocitinib PO QD, Placebo PO QD
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
53
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

NCT04405570
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
Molnupiravir 200 mg, Molnupiravir 400 mg, Molnupiravir 800 mg, Placebo (PBO)
Drug
Lead sponsor
Ridgeback Biotherapeutics, LP
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Northridge, California • Oxnard, California • Yucaipa, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 23, 2026, 6:09 AM EDT
Recruiting Phase 3 Interventional

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

NCT03808922
View directory record Official record
Conditions
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Interventions
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
Not listed
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
23
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 6:09 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Many Men, Many Voices, An STD/HIV Prevention Intervention for Black MSM

NCT00137631
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Many Men, Many Voices (3MV)
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older · Male only
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2010 · Synced Oct 23, 2026, 6:09 AM EDT